Improved mature polypeptide
By modifying the amino acid sequence of β-galactosidase, mature polypeptides and mutants that efficiently catalyze LNT and LNnT were developed, which solved the problem of low production efficiency of HMOs in the prior art, and achieved lactose-N-tetrasaccharide and The efficient synthesis of lactose-N-new tetrasucosaccharide has promoted its widespread use in a variety of food and dietary supplements.
Patent Information
- Application Number
- PCT/CN2024/088498
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-11
- Filing Date
- 2024-04-18
- Publication Date
- 2024-11-14
Smart Images

Figure CN2024088498_14112024_PF_FP_ABST
Abstract
Description
An improved mature peptide
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to Chinese patent application CN202310538564.X, entitled “An Improved Mature Polypeptide,” filed on May 11, 2023. The entire contents of the above application are incorporated herein by reference for all purposes. Technical Field
[0003] The present application relates to an improved mature polypeptide and its application in synthesizing human milk oligosaccharides, belonging to the field of gene and enzyme engineering technology. Background Art
[0004] The information disclosed in this background technology section is only intended to enhance understanding of the overall background of the application, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to those skilled in the art.
[0005] Human milk oligosaccharides (HMOs) are a class of natural oligosaccharide mixtures found only in breast milk and are also important functional components of breast milk. Studies have found that HMOs play an important role in infant intestinal health, immune system regulation, physical growth, and brain cognitive development. Among them, lactose-N-tetraose (LNT) is the most abundant HMO in breast milk and is a representative of neutral HMOs, with the chemical formula shown in Formula 1. It is the core structure shared by other long-chain HMOs and many glycolipids. Lactose-N-neotetraose (LNnT) is an isomer of LNT, with the chemical formula shown in Formula 2. LNT and LNnT are important components of breast milk and have multiple functions. The proportions of the two in breast milk vary greatly, with LNT being more abundant, approximately eight times that of LNnT (Craft KM, Townsend SD. Synthesis of lacto-N-tetraose. Carbohydr Res. 2017 Feb 22; 440-441: 43-50.).
[0006] For infants and young children who cannot be breastfed, LNnT, as a food nutrient fortifier, is permitted in children's formula milk powder, infant formula, and special medical purpose formula at a dosage of 0.2-0.6 g / L (pure form, ready-to-feed; for powdered products, the dosage increases based on the number of times the formula is prepared, according to the 2022 draft for public comment by the Food and Drug Administration). The maximum dosage of LNT, lactic acid-N-tetraose, in infant formula is 1.82 g / L (approved by the EU in 2023, manufactured by Chr. Hansen). Previously, the approved dosage ranged from 0.6-0.8 g / L. Therefore, with increasing awareness of HMOs and advancements in production technology, a trend toward using higher concentrations of HMOs in infant formula and other foods has emerged. While HMOs are currently primarily used in infant formula, their significant health benefits extend beyond infants. With economic development, demand for human milk oligosaccharides will gradually increase.
[0007] Developing simple, efficient, low-cost methods for the large-scale industrial production of HMOs to meet societal needs is a challenge for HMO research institutions and companies. Chinese patent CN111534503A discloses a method for synthesizing lactose-N-neotetraose (LNnT): β-galactosidase catalyzes the synthesis of lactose-N-neotetraose from lactose-N-triose and β-lactose; alternatively, chitinase, HaHex74 protein, and β-galactosidase are used as enzymes to catalyze the synthesis of lactose-N-triose II and lactose-N-neotetraose from chitin and β-lactose.
[0008] In summary, in order to meet social needs, it is necessary to iterate the existing HMOs production technology, and providing efficient and scalable production technology is an urgent task.
[0009] Summary of the Invention
[0010] Purpose of the Invention: Efficient, large-scale production of both LNT and LNnT would facilitate rapid formulation and use in dairy products, baked goods, beverages, dietary supplements, special medical formulas, and infant foods. This application aims to provide mature polypeptides with strong catalytic activity in the synthesis of lactose-N-tetraose (LNT) and lactose-N-neotetraose (LNnT), as well as their use in the catalytic synthesis of LNT and LNnT. Currently, no biosynthetic technology capable of simultaneously synthesizing lactose-N-tetraose and lactose-N-neotetraose has been identified.
[0011] In addition, the present application also provides related nucleic acid products, enzyme products, and preparation methods and applications thereof.
[0012] Technical solution:
[0013] A mature polypeptide, β-galactosidase WP_127489039.1, is derived from Neobacillus mesonae, and its amino acid sequence is shown in SEQ ID NO: 1. In the examples, it is referred to as D1, and has the activity of catalyzing the synthesis of lactose-N-tetraose and lacto-N-neotetraose.
[0014] The β-galactosidase is an enzyme that can hydrolyze β-D-galactosidic bonds to release D-galactose. It is widely present in microorganisms, animals and plants. Its species sources include but are not limited to: Aspergillus oryzae, Kluyveromyces lactis, Kluyveromyces marxinus, Bacillus subtilis, Bacillus circulans, etc., and further preferred species sources are Bacillus circulans or Bacillus subtilis, etc.
[0015] The applicant has made a series of improvements to the glycoside hydrolase with the amino acid sequence shown in SEQ ID NO: 1, thereby improving the activity of synthesizing lactose-N-tetraose and lacto-N-neotetraose while retaining the activity of synthesizing lactose-N-tetraose and lacto-N-neotetraose.
[0016] Specifically, in the first aspect, the present application provides an amino acid sequence as shown in SEQ ID NO: 1, which is formed by modifying multiple amino acid residues and has glycoside hydrolase activity as shown in SEQ ID NO: 1; wherein the modification of the multiple amino acid residues is selected from the modification of one or more amino residues at positions 182-189, 408-413, 449-454, 481-492, 561-569, 571-573, 591-597, 599-606, etc. in the mature polypeptide of the amino acid sequence as shown in SEQ ID NO: 1. After the above modification, a mutant of the mature polypeptide as shown in SEQ ID NO: 1 is obtained, which is referred to as a mature polypeptide mutant or mutant in this application.
[0017] The mutant of the mature polypeptide has improved catalytic synthesis of LNT and LNnT.
[0018] The modification refers to any chemical modification of the polypeptide or its homologous sequence composed of the mature polypeptide, as well as genetic manipulation of the DNA encoding the polypeptide. The modification can be the replacement and / or insertion of one or more (several) amino acid residues.
[0019] Preferably, the modification of one or more amino acid residues in the mature polypeptide of SEQ ID NO: 1 is selected from one or more of the following schemes: the modifications described below are all based on the sequence of SEQ ID NO: 1;
[0020] The amino acid residues at positions 182-185 are substituted from QPSS to GMNC, the amino acid residue at position 189 is substituted from S to T, and the amino acid residues at positions 408-412 are substituted from QSKKP to YGHYQ to obtain mutant D2, the amino acid sequence of which is shown in SEQ ID NO: 2; and / or
[0021] The amino acid residues at positions 408-413 are substituted from QSKKPY to PMNRLT, the amino acid residues at positions 481-482 are substituted from ED to DN, and the amino acid residues at positions 484-492 are substituted from TRGDKVNVT to IKANWNESN, to obtain mutant D3, the amino acid sequence of which is shown in SEQ ID NO: 3; and / or
[0022] The amino acid residues at positions 450-454 are replaced by YDTTN to KNKET, the amino acid residues at positions 567-569 are replaced by DYV to SLG, and the amino acid residues at positions 571-573 are replaced by WGR to FAK, to obtain mutant D4, the amino acid sequence of which is shown in SEQ ID NO: 4; and / or
[0023] The amino acid residues at positions 182-184 are substituted from QPS to RAD, the amino acid residue at position 189 is substituted from S to T, the amino acid residues at positions 408-413 are substituted from QSKKPY to PMNRLT, the amino acid residue at position 593 is substituted from I to V, the amino acid residue at position 600 is substituted from I to L, and the amino acid residue at position 606 is substituted from Y to W, to obtain mutant D5, the amino acid sequence of which is shown in SEQ ID NO: 5; and / or
[0024] The amino acid residues at positions 182-184 are substituted from QPS to RAD, the amino acid residue at position 189 is substituted from S to T, the amino acid residues at positions 408-413 are substituted from QSKKPY to PMNRLT, the amino acid residues at positions 449-453 are substituted from IYDTT to SGHGA, the amino acid residue at position 593 is substituted from I to V, the amino acid residue at position 600 is substituted from I to L, and the amino acid residue at position 606 is substituted from Y to W, to obtain mutant D6, whose amino acid sequence is shown in SEQ ID NO: 6; and / or
[0025] Amino acid residues at positions 182-185 are substituted from QPSS to GMNC, amino acid residue 189 is substituted from S to T, amino acid residues 408-412 are substituted from QSKKP to YGHYQ, amino acid residues 481-482 are substituted from ED to DN, amino acid residues 484-492 are substituted from TRGDKVNVT to IKANWNESN, amino acid residues 567-568 are substituted from DY to SA, amino acid residue 573 is substituted from R to A, amino acid residue 593 is substituted from I to V, amino acid residues 595-597 are substituted from TGF to DWV, and amino acid residues 599-606 are substituted from YIGEPTPY to QSLIKYDE, to obtain mutant D7, the amino acid sequence of which is shown in SEQ ID NO: 7; and / or
[0026] The amino acid residues at positions 182-185 are substituted from QPSS to GMNC, the amino acid residue at position 189 is substituted from S to T, the amino acid residues at positions 408-413 are substituted from QSKKPY to PMNRLT, the amino acid residues at positions 450-454 are substituted from YDTTN to KNKET, the amino acid residues at positions 567-569 are substituted from DYV to SLG, and the amino acid residues at positions 571-573 are substituted from WGR to FAK, to obtain mutant D8, the amino acid sequence of which is shown in SEQ ID NO: 8; and / or
[0027] Amino acid residues at positions 450-454 are substituted from YDTTN to KNKET, amino acid residue 481 is substituted from E to A, amino acid residue 484 is substituted from T to F, amino acid residues 486-492 are substituted from GDKVNVT to FGNGSGG, amino acid residues 567-569 are substituted from DYV to SLG, amino acid residues 571-573 are substituted from WGR to FAK, amino acid residue 593 is substituted from I to V, amino acid residues 595-597 are substituted from TGF to DWV, and amino acid residues 599-606 are substituted from YIGEPTPY to QSLIKYDE, to obtain mutant D9, the amino acid sequence of which is shown in SEQ ID NO: 9; and / or
[0028] amino acid residues 182-184 are substituted from QPS to RAD, amino acid residue 189 is substituted from S to T, amino acid residues 449-453 are substituted from IYDTT to SGHGA, amino acid residue 481 is substituted from E to A, amino acid residue 484 is substituted from T to F, amino acid residues 486-492 are substituted from GDKVNVT to FGNGSGG, amino acid residues 567-568 are substituted from DY to SA, amino acid residue 573 is substituted from R to A, amino acid residue 593 is substituted from I to V, amino acid residues 595-597 are substituted from TGF to DWV, and amino acid residues 599-606 are substituted from YIGEPTPY to QSLIKYDE, to obtain mutant D10, the amino acid sequence of which is shown in SEQ ID NO: 10; and / or
[0029] The amino acid residues at positions 182-185 were replaced by QPSS to GMNC, the amino acid residue at position 189 was replaced by S to T, the amino acid residues at positions 408-413 were replaced by QSKKPY to PMNRLT, the amino acid residues at positions 449-453 were replaced by IYDTT to SGHGA, the amino acid residue at position 481 was replaced by E to A, the amino acid residue at position 484 was replaced by T to F, the amino acid residues at positions 486-492 were replaced by GDKVNVT to FGNGSGG, the amino acid residues at positions 567-568 were replaced by DY to SA, the amino acid residue at position 573 was replaced by R to A, the amino acid residue at position 593 was replaced by I to V, the amino acid residues at positions 595-597 were replaced by TGF to DWV, and the amino acid residues at positions 599-606 were replaced by YIGEPTPY to QSLIKYDE, to obtain the mutant D11, the amino acid sequence of which is shown in SEQ ID Shown in NO:11.
[0030] Preferably, the mature polypeptide and / or the mutant of the mature polypeptide, including but not limited to polypeptides having an amino acid sequence with at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1 and / or SEQ ID NO: 2 and / or SEQ ID NO: 3 and / or SEQ ID NO: 4 and / or SEQ ID NO: 5 and / or SEQ ID NO: 6 and / or SEQ ID NO: 7 and / or SEQ ID NO: 8 and / or SEQ ID NO: 9 and / or SEQ ID NO: 10 and / or SEQ ID NO: 11, has an improved ability to catalyze the synthesis of lactose-N-tetraose and lactose-N-neotetraose.
[0031] In a second aspect, the present application provides a polynucleotide encoding the polypeptide as described in the first aspect above.
[0032] In a third aspect, the present application provides a nucleic acid construct comprising the polynucleotide as described in the second aspect above, and one or more regulatory sequences operably linked thereto, wherein the regulatory sequences can direct the production of the polypeptide in a suitable expression host.
[0033] In a fourth aspect, the present application provides an expression vector comprising the polynucleotide as described in the second aspect above, or comprising the nucleic acid construct as described in the third aspect above.
[0034] In a fifth aspect, the present application provides a transformed host cell, into which the nucleic acid construct as described in the third aspect or the expression vector as described in the fourth aspect is transformed.
[0035] In a sixth aspect, the present application further provides an enzyme agent or enzyme composition, which comprises a mature polypeptide or a mutant thereof having an amino acid sequence as shown in SEQ ID NO: 1.
[0036] Preferably, the composition contains one or more polypeptides comprising an amino acid sequence having at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the polypeptide shown in SEQ ID NO: 1 and / or SEQ ID NO: 2 and / or SEQ ID NO: 3 and / or SEQ ID NO: 4 and / or SEQ ID NO: 5 and / or SEQ ID NO: 6 and / or SEQ ID NO: 7 and / or SEQ ID NO: 8 and / or SEQ ID NO: 9 and / or SEQ ID NO: 10 and / or SEQ ID NO: 11.
[0037] In a seventh aspect, the present application further provides a method for expressing a mature polypeptide having an amino acid sequence as shown in SEQ ID NO: 1 and / or a mutant thereof, comprising the following steps:
[0038] (a) culturing a host cell under conditions suitable for expressing the mature polypeptide having an amino acid sequence as shown in SEQ ID NO: 1 and / or a mutant thereof; and
[0039] (b) recovering the mature polypeptide and / or its mutants having the amino acid sequence shown in SEQ ID NO: 1.
[0040] Preferably, step (a) comprises culturing a host cell comprising a nucleic acid construct comprising a nucleotide sequence encoding the polypeptide under conditions conducive to production of the polypeptide.
[0041] Preferably, the step (a) further comprises first constructing a recombinant plasmid encoding the mature polypeptide shown in SEQ ID NO: 1 and / or its mutant gene, and then introducing it into a host cell.
[0042] Preferably, the host cell in step (a) comprises a recombinant engineered strain of host cell.
[0043] Preferably, step (a) comprises: first introducing a nucleic acid construct or a recombinant expression vector encoding the mature polypeptide or a mutant thereof as shown in SEQ ID NO: 1 into a host cell to construct an engineered host cell expressing the mature polypeptide or a mutant thereof as shown in SEQ ID NO: 1; then, culturing the engineered host cell and inducing it to express the mature polypeptide or a mutant thereof as shown in SEQ ID NO: 1.
[0044] Preferably, step (a) comprises: first, designing mutation primers for site-directed mutagenesis according to the determined mutation site, and performing site-directed mutagenesis using a vector carrying the β-galactosidase gene as a template; constructing a plasmid vector containing a gene encoding a mature polypeptide or a mutant thereof with an amino acid sequence as shown in SEQ ID NO: 1; and then transforming the plasmid into a host cell.
[0045] Preferably, the step (b) further comprises isolating and purifying the mature polypeptide having an amino acid sequence as shown in SEQ ID NO: 1 and / or its mutants.
[0046] Preferably, the step (b) comprises: after the expression is completed, disrupting the cultured cells to obtain a crude enzyme solution containing the mature polypeptide shown in SEQ ID NO: 1 or a mutant thereof; optionally, further comprising the step of isolating and purifying the mature polypeptide or a mutant thereof having an amino acid sequence as shown in SEQ ID NO: 1.
[0047] Preferably, the step (b) comprises: selecting positive clones for fermentation culture, centrifuging, and obtaining a crude enzyme solution having an amino acid sequence as shown in SEQ ID NO: 1, a mature polypeptide or a mutant thereof.
[0048] Preferably, the separation and purification step can be performed by conventional protein purification methods, such as ion exchange chromatography, hydrophobic chromatography, gel filtration chromatography, salting out, etc. or a combination thereof; further preferably, purification can be performed by Ni column affinity chromatography.
[0049] Preferably, in the method for expressing the mature polypeptide represented by SEQ ID NO: 1 and / or its mutants, the host cell is selected from yeast cells, bacterial cells or molds.
[0050] Preferably, the host cell is selected from the genera Bacillus and Escherichia; further preferably, selected from Escherichia coli, Escherichia hermanii, Escherichia fergusonii, Bacillus mycoides, Bacillus cereus, Bacillus licheniformis, Bacillus brevis, Bacillus circulans and Bacillus subtilis.
[0051] Further preferably, the host cell is Bacillus circulans, Bacillus subtilis or Bacillus licheniformis.
[0052] Preferably, the mold is selected from the genera Aspergillus and Trichoderma; further preferably, it is a Trichoderma viride, Trichoderma reesei, Aspergillus oryzae, Aspergillus fumigatu, Aspergillus niger, or Aspergillus flavus cell; further preferably, the host cell is an Aspergillus oryzae cell.
[0053] Preferably, the yeast cell is selected from the group consisting of: Candida, Hansenula, Kluyveromyces, Pichia, Saccharomyces, Schizosaccharomyces, or Yarrowia cells; more preferably, it is a cell of Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces marxinus, Yarrowia lipolytica, Rhodotorula graminis, Saccharomyces pastorianus, etc.; further preferably, it is a cell of Saccharomyces cerevisiae, Kluyveromyces lactis, or Kluyveromyces marxinus.
[0054] Preferably, in the method for expressing the mature polypeptide shown in SEQ ID NO: 1 or a mutant thereof, the host cell includes a wild strain isolated from nature, a mutant strain after physical and chemical mutagenesis, or an engineered bacterium after genetic engineering.
[0055] Host cells can be cultivated in a nutrient medium suitable for producing mature polypeptide and / or mature polypeptide mutant using methods known in the art. For example, it is possible to culture by shaking a flask, or in a suitable substratum and under the condition of allowing mature polypeptide and / or mature polypeptide mutant to express and / or separate, in a laboratory or an industrial fermentor, carry out small-scale or large-scale fermentation (comprising continuous fermentation, batch fermentation, batch-fed fermentation or solid-state fermentation) to cultivate cells. Cultivation is to use a program known in the art, and in being applicable to a nutrient medium, it occurs that the substratum comprises carbon and nitrogen sources and inorganic salts. The substratum applicable can be purchased through commercial channels, or prepared according to disclosed composition.
[0056] The mature polypeptide or mutant thereof having an amino acid sequence as shown in SEQ ID NO: 1 can be recovered using methods known in the art. For example, the variant can be recovered from the nutrient medium by various conventional procedures, including but not limited to collection, centrifugation, filtration, extraction, spray drying, evaporation or precipitation.
[0057] The mature polypeptide and / or its mutant can be purified by various procedures known in the art to obtain substantially pure mature polypeptide and / or its mutant, including but not limited to chromatography (e.g., ion exchange chromatography, affinity chromatography, hydrophobic interaction chromatography, gel filtration chromatography), electrophoresis procedures (e.g., preparative isoelectric focusing), differential solubility methods (e.g., ammonium sulfate precipitation), SDS-PAGE, salting out, etc. or a combination thereof for separation or purification. Further preferably, purification can also be performed by Ni column affinity chromatography.
[0058] In an eighth aspect, the present application provides a synthetic method for producing LNT and LNnT, comprising: using the mature polypeptide shown in SEQ ID NO: 1 or a mutant thereof as a catalyst to catalyze the reaction of lactose with lactose-N-triose (Lacto-N-triose, LNTII) to produce LNT and LNnT.
[0059] In some embodiments, the use of the mature polypeptide represented by SEQ ID NO: 1 or a mutant thereof, or a combination thereof, in the production of LNT and LNnT is described.
[0060] Preferably, the application includes the steps of generating LNT and LNnT.
[0061] Preferably, in the method or the use, a carbohydrate selected from lactose and / or its derivatives is used as a reaction substrate.
[0062] Preferably, in the method or use, lactose and lactose-N-triose are used as reaction substrates.
[0063] Preferably, in the method or application, an aqueous solvent or a solution containing solids is used as the reaction solvent.
[0064] Preferably, in the method or application, the culture medium containing the mature polypeptide and / or its mutant can be directly used; preferably, the mature polypeptide and / or its mutant is purified and then used as a catalyst.
[0065] Preferably, in the method or application, process parameters such as temperature, enzyme addition amount, reaction time, pH, etc. can be studied or selected according to the method disclosed in this application.
[0066] definition:
[0067] The terms "mature polypeptide" and "mature polypeptide mutant" refer to the portion of a polypeptide sequence after any post-translational sequence or sequence modification, such as the known sequence, N-terminal processing, truncation, and / or C-terminal truncation thereof. In one aspect, "mature polypeptide" and "mature polypeptide mutant" are both "mature polypeptides," and the mature polypeptides and mutants thereof described herein include proteins set forth in SEQ ID NOs: 1-11.
[0068] The term "host cell" refers to any cell type that is susceptible to transformation, transfection, transduction, etc. with an expression vector. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to substitutions that occur during replication.
[0069] The term "nucleic acid construct" refers to an artificially constructed nucleic acid fragment, particularly a DNA fragment, which is intended to be "transplanted" into a target cell (e.g., a bacterial cell) to modify the expression of genomic genes or to express genes / coding DNA sequences that may be included in the construct. Beneficial effects
[0070] This application provides a series of novel mature polypeptide mutants and expression methods. These mature polypeptide mutants retain and enhance the activity of the mature polypeptide of SEQ ID NO: 1 in catalyzing the synthesis of LNT and LNnT. The methods for catalyzing the synthesis of LNT and LNnT using the mature polypeptide mutants described in this application are simple, environmentally friendly, and highly efficient.
[0071] The present application provides for the first time a mature polypeptide and a mutant thereof having the activity of catalyzing the synthesis of LNT and LNnT. The obtained product can be eaten directly or after being mixed with other ingredients as needed. BRIEF DESCRIPTION OF THE DRAWINGS
[0072] The drawings constituting part of the present application are used to provide a further understanding of the present application. The exemplary embodiments and descriptions of the present application are used to explain the present application and do not constitute an improper limitation of the present application. The following describes the implementation scheme of the present application in detail with reference to the drawings.
[0073] in:
[0074] Figure 1 shows the mass spectra of LNT and LNnT. DETAILED DESCRIPTION
[0075] The following provides methods for expressing the mature polypeptide and / or its mutants described in this application, as well as examples of their applications.
[0076] The experimental methods used in the following examples are conventional methods unless otherwise specified; all materials, reagents, etc., are commercially available unless otherwise specified.
[0077] The present application is further described in detail below through examples. It should be understood that the specific implementation methods described here are only used to explain the present application and are not used to limit the present application. Modifications or replacements to the details and forms of the technical solution without departing from the structural ideas and scope of use of the present application fall within the scope of protection of the present application.
[0078] Unless otherwise defined, all technical and scientific terms used in this specification have the same meanings as those commonly understood by those skilled in the art. In general, the nomenclature used in this specification and the experimental methods described below are well known and commonly used in the art.
[0079] In the following examples and test examples, the products obtained from the catalytic reaction of the mature polypeptide and / or mature polypeptide mutant were analyzed and identified using HPLC analysis method and ion chromatography.
[0080] HPLC analysis conditions are as follows: a 4.6×250 mm, 5 μm Asahipak NH2P-504E amino column was used, and 65% acetonitrile aqueous solution was used as the mobile phase for isocratic elution; the flow rate was 0.5 mL / min, the column temperature was 30°C, the injection volume was 10 μL, and the detection wavelength was 195 nm using an ultraviolet detector.
[0081] The ion chromatography analysis conditions were as follows: chromatographic column: MetroSep Carb2 (4.0 mm × 250 mm), eluent: 140 mM NaOH + 20 mM NaAc, isocratic elution, flow rate: 0.500 mL / min, amperometric detector, column temperature 40 °C, injection volume 20 μL, run time 50 min.
[0082] Lactose-N-triose (LNTⅡ), lactose-N-tetraose (LNT), and lactose-N-neotetraose (LNnT) standards were produced by ELICITYL, France.
[0083] It should be noted that the terms used herein are only for the purpose of describing specific embodiments and are not intended to limit the exemplary embodiments according to the present application. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, they indicate the presence of features, steps, operations and / or combinations thereof. It should be understood that the scope of protection of the present application is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present application are for the purpose of describing specific embodiments and are not intended to limit the scope of protection of the present application. In the following specific embodiments, if the experimental methods for specific conditions are not specified, they are generally in accordance with the conventional methods and conditions of molecular biology within the technology of the art, and such techniques and conditions are fully explained in the literature. See, for example, Sambrook et al., the techniques and conditions described in "Molecular Cloning: A Laboratory Manual", or in accordance with the conditions recommended by the manufacturer.
[0084] Example 1. Expression of mature polypeptides and / or mature polypeptide mutants in E. coli
[0085] Using protein engineering techniques combined with high-throughput screening, we modified the glycosidase with the amino acid sequence shown in SEQ ID NO: 1, generating a series of mutants with significantly improved efficiency in catalyzing the synthesis of LNT and LNnT. The specific steps are as follows:
[0086] By codon optimization and DNA synthesis, the gene corresponding to the mature polypeptide and / or its mutant shown in SEQ ID NO: 1 was obtained. Referring to the method of the Molecular Cloning Experiment Guide, the pET32a-BgaD-D1-11 series of plasmids / or recombinant plasmid series were constructed, as shown in Table 1. The above recombinant plasmids were transformed into Escherichia coli BL21 (DE3) according to the following steps: Take the prepared Escherichia coli BL21 (DE3) competent cells, place them on ice for 30 minutes to melt, take 100 μL of competent cells and mix them with 10 μL of pET32a-BgaD-D1-11 plasmid / or recombinant plasmid (concentration 50 ng / μL), let it stand for 30 minutes, place it in a 42°C water bath for heat shock for 45 seconds, then immediately cool it in an ice bath for 2 minutes, add 700 μL of fresh LB medium (LB medium: peptone 1.0%, yeast extract 0.5%, NaCl 1.0% agar (1.5% agar powder added to the plate) was resuscitated and cultured at 37°C, 220 rpm for 1 hour. Afterwards, 100 μL of the bacterial solution was spread onto LB plates containing ampicillin (100 μg / mL). After incubation at 37°C for 12 hours, single colonies were selected for PCR. Primer sequences are shown in Table 1 to screen for positive transformants. Furthermore, after culturing correct transformants, their plasmids were extracted, and PCR amplification, double enzyme digestion, and gene sequencing were used to verify the successful introduction of the pET32a-BgaD-D1-11 series plasmids and / or recombinant plasmids into E. coli.
[0087] Then, the correct transformant was inoculated into LB liquid medium and cultured on a shaker at 37°C and 200 rpm for 12 h to obtain seed solution. The seed solution was then inoculated into fresh LB medium at a 1% (v / v) inoculum and cultured at 37°C with shaking until the OD 600 The expression level was 0.8, and the cells were induced with isopropyl-β-D-thiogalactopyranoside (IPTG) at a final concentration of 0.05 mmol / L for 12 hours at 16°C and 200 rpm. After induction, the fermentation broth was centrifuged at 6000 rpm for 10 minutes at 4°C to collect the cells. The cells were resuspended in 20 mM imidazole (PBS) buffer (pH 7.4) and disrupted by sonication for 20 minutes at a rate of 5 seconds on / 5 seconds off. The resulting suspension was centrifuged at 12,000 × g at 4°C for 30 minutes to remove cell debris, and the supernatant was collected.
[0088] The mature polypeptide or mutant thereof represented by SEQ ID NO:1 was purified using nickel column affinity chromatography. The process was as follows: deionized water was added to the nickel column to the top of the column. After natural elution, the purified product was eluted with 5 volumes of Binding Buffer. The crude enzyme solution, filtered through a 0.45 μm filter, was then applied to the column. The sample was allowed to fully bind to the nickel column at a flow rate of 1.5 mL / min. After the sample was drained, it was continuously eluted with 5 column volumes of Washing Buffer for a gradient elution to remove contaminants. Finally, the target protein was eluted with 5 volumes of Elution Buffer, and the eluate was collected. The expression of the target protein was then analyzed by SDS-PAGE. After induction, the genetically engineered bacteria showed a distinct specific expression band, and the molecular weight of the band was substantially consistent with the expected molecular weight of 90.77 kDa, thus obtaining the mature polypeptide and / or mutant thereof represented by SEQ ID NO:1.
[0089] Table 1. Mature polypeptide represented by SEQ ID NO: 1 and its mutants and corresponding recombinant plasmids and primers
[0090] Table 2. Correspondence between recombinant plasmids and mutants
[0091] Example 2. Catalytic synthesis of the mature polypeptide represented by SEQ ID NO: 1 and its mutants
[0092] Study on the synthesis of lactose-N-tetraose (LNT) and lactose-N-neotetraose (LNnT) catalyzed by the mature polypeptide shown in SEQ ID NO: 1 and its mutants (after purification).
[0093] The purified mature polypeptide shown in SEQ ID NO: 1 obtained in Example 1 or its mutant was subjected to enzymatic catalysis, specifically, 128 mM lactose and 20 mM lactose-N-triose (Lacto-N-triose II, LNTII) were added to the mature polypeptide (D1) and / or its mutant (D2-11) described in Table 3, 10 mM MgCl2, and 100 mM phosphate buffer (pH 8), and the volume was adjusted to 5 mL. The mixture was mixed and reacted at 40°C for the time described in Table 3. The reaction was terminated and the product was purified by gel column method.
[0094] Identification of catalytic synthesis products:
[0095] High performance liquid chromatography (HPLC), LC-MS analysis methods, and ion chromatography were used to analyze the products of the reaction catalyzed by lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT) standards and the mature polypeptide shown in SEQ ID NO: 1, or its mutants.
[0096] The HPLC analysis conditions were as shown above, and the analysis results showed:
[0097] (1) The peak time rt of LNT and LNnT standards is 15.800 min.
[0098] (2) In this example, the reaction solution catalyzed by the mature polypeptide shown in SEQ ID NO: 1 or its mutants showed a strong absorption peak at around 15.800 min at a wavelength of 195 nm, which was consistent with the peak time of LNT and LNnT standards, indicating that lactose-N-tetraose (LNT) and / or lactose-N-neotetraose LNnT may have been synthesized in the reaction solution.
[0099] LC-MS analysis
[0100] The product at rt=15.800 min in the HPLC spectrum was subjected to LC-MS analysis.
[0101] The mass spectra of the lactose-N-neotetraose (LNnT) standard are the same as those of the lactose-N-tetraose (LNT) standard.
[0102] As shown in Figure 1, the molecular weight of 708.2567 should be LNnT / LNT+H; the molecular weight of 730.2393 should be LNnT / LNT+Na. The mass spectrometry results can be searched to obtain the following results: Compound CID: 440993, Chemical Formula: C 26 H 45 NO 21 , Extract Mass:707.63.
[0103] The mass spectrometry results of the reaction solution of the mature polypeptide of SEQ ID NO: 1 or its mutants at rt = 15.800 min in this example were the same as those in FIG1 . Therefore, it is speculated that the mature polypeptide of SEQ ID NO: 1 or its mutants synthesized a substance with a molecular weight of approximately 707, which may be lacto-N-neotetraose (LNnT) and / or lacto-N-tetraose (LNT).
[0104] The results of ion chromatography analysis showed that:
[0105] (1) The peak elution time of lactose-N-neotetraose (LNnT) standard was 26.99 min; the peak elution time of lactose-N-tetraose (LNT) standard was 30.92 min.
[0106] (2) In this example, the substance with rt = 15.800 min from the reaction solution of the mature polypeptide shown in SEQ ID NO: 1 or its mutant was respectively intercepted and analyzed by ion chromatography, and the following results were obtained:
[0107] in conclusion
[0108] As shown by the above HPLC, LC-MS and ion chromatography analysis results, the mature polypeptide shown in SEQ ID NO: 1 or its mutants catalyze the catalytic reaction with lactose and lactose-N-triose (Lacto-N-trioseⅡ) as substrates.
[0109] The catalytic reactions synthesized lactose-N-neotetraose (LNnT) and lactose-N-tetraose (LNT).
[0110] The yields of lactose-N-tetraose (LNT) and / or lactose-N-neotetraose (LNnT) in the reaction solution were determined by ion chromatography. The results are recorded in Table 3.
[0111] Table 3. Studies on the synthesis of LNT and LNnT catalyzed by the mature polypeptide shown in SEQ ID NO: 1 or its mutants
[0112] Table 3 Data Description:
[0113] (1) Both the mature polypeptide D1 and the mature polypeptide mutants D2-D11 have the activity of catalyzing the synthesis of LNT and LNnT.
[0114] (2) The mature polypeptide mutants D2, D3, D5, D6, D7, D9, D10, and D11 have high catalytic activity in the synthesis of LNT and LNnT.
[0115] Example 3. Expression of mature polypeptide mutants D3 and D10 in Kluyveromyces lactis
[0116] The construction method of recombinant plasmids pKLAC1-D3 and pKLAC1-D10 is as follows:
[0117] PCR amplification was performed based on the gene sequence of the mature polypeptide mutants D3 or D10. The PCR reaction system (50 μL) consisted of 1 μL DNA template, 25 μL 2× Phanta Max Buffer, 1 μL 10 pmol / μL dNTP Mix, 2 μL each of 10 pmol / μL forward and reverse primers, and 1 μL 1 U / μL Phanta Max Super-Fidelity DNA Polymerase, with ddH2O added to 50 μL. The PCR reaction protocol was as follows: 95°C for 3 min, followed by 33 cycles of 95°C for 15 s, 60°C for 15 s, and 72°C for 1.5 min, followed by 72°C for 5 min, and storage at 4°C. The PCR fragment and plasmid fragment were double-digested with restriction endonucleases XmajI and NotI, respectively, and then ligated with ligation high ligase. The fragments were then transformed into Escherichia coli DH5α, and the recombinant plasmids pKLAC1-D3 or pKLAC1-D10 were obtained after screening and identification.
[0118] Next, amplify the KLAC1-D3 or KLAC1-D10 expression cassette using PCR amplification using primers designed based on the pklac1 plasmid sequence. The PCR reaction system (50 μL) includes 1 μL (approximately 50 ng) of DNA template (pklac1-BgaD-D3 or pklac1-BgaD-D10), 25 μL of 2× Phanta Max Buffer, 1 μL of 10 pmol / μL dNTP Mix, 2 μL of each 10 pmol / μL forward and reverse primer, and 1 μL of 1 U / μL Phanta Max Super-Fidelity DNA Polymerase. Add ddH2O to 50 μL. The PCR reaction procedure is the same as above. After agarose gel electrophoresis, the KLAC1-D3 or KLAC1-D10 expression cassette is recovered.
[0119] Subsequently, the KLAC1-D3 or KLAC1-D10 expression cassette was transformed into Kluyveromyces lactis CICC1773 as follows: a freshly cultured Kluyveromyces lactis colony was picked and transferred to 1 mL of YPD medium, and the culture was placed in a constant temperature shaker at 30°C and 250 rpm for 12-14 hours; the culture was transferred to 50 mL of fresh YPD medium with an initial inoculum OD of 0.2 and cultured at 30°C and 200 rpm for 3-4 hours to an OD of 0.8-1; the bacterial culture was placed on ice for 5-10 minutes, and at the same time, 25 μL of salmon sperm DNA (2 mg / mL) was incubated in a PCR instrument at 95°C for 10 minutes, then quickly cooled in an ice-water bath and placed on ice until ready for use; the expression cassette solution to be transformed was prepared by adding a total of 5-10 μg to each tube and making up to 50 μL with sterile ddH2O. After standing on ice, the culture medium was centrifuged at 4°C and 5000×g for 5 minutes, the supernatant was discarded, and the bacteria were collected; the bacteria were resuspended in sterile ddH2O, centrifuged at 4°C and 5000×g for 5 minutes, the supernatant was discarded, and the bacteria were collected, and repeated once; 1mL of 0.1M LiCl solution was added to resuspend the bacteria, transferred to a new 1.5mL centrifuge tube, centrifuged at 4°C and 13000×g for 15 seconds, and the supernatant was discarded; 400μL of 0.1M LiCl solution was added to resuspend the bacteria, and the tubes were divided into 50μL per tube, centrifuged at 4°C and 13000×g for 15 seconds, and the supernatant was discarded and placed on ice for use; 240μL of 50% PEG3350 solution and 1M Add 36 μL of LiCl solution, 25 μL of pretreated salmon sperm DNA solution, and 50 μL of the expression cassette solution to be transformed. Vortex vigorously until the cells are completely distributed (approximately 5 minutes). Place the thoroughly mixed system in a 30°C water bath for 30 minutes. Heat shock the system in a 42°C water bath for 25 minutes. Centrifuge the cells at room temperature at 8000 × g for 2 minutes, harvest the cells, resuspend them in 1 mL of YPD, and incubate them on a shaker at 30°C for 1-4 hours. Apply 25-135 μL of the bacterial solution to a G418-resistant culture plate. Place the plate in a 30°C incubator and incubate upside down for 2-3 days. Select transformants to verify successful expression cassette integration.
[0120] The shake flask fermentation was performed as follows: 1) Preparation of the primary strain: A single colony of the above-mentioned genetically engineered yeast strain was cultured overnight in 10 mL of YGD liquid medium at 30°C and 200 rpm. The resulting strain was the primary strain. 2) Preparation of the secondary strain: The primary strain was inoculated into 1 mL of YGD liquid medium and cultured at 30°C and 200 rpm until the OD 6003) The YGD culture medium was centrifuged to obtain a crude enzyme solution of the target protein, which was then purified according to the method in Example 1. The resulting proteins were mature polypeptide mutants KL-D3 and KL-D10, respectively, with amino acid sequences shown in SEQ ID NO: 3 and SEQ ID NO: 10, respectively.
[0121] KL-D3 and KL-D10 were used for enzyme catalysis, and their ability to catalyze the synthesis of LNT and LNnT was determined.
[0122] Specifically, 128 mM lactose, 20 mM lactose-N-triose II (LNTII), 0.3 mg / mL of the mature polypeptide mutant KL-D3 or KL-D10, 10 mmol / L MgCl2, and 100 mM phosphate buffer (pH 8) were added to a volume of 5 mL, mixed, and reacted at 40°C for 24 hours. The reaction was terminated and the product was purified using a gel column method. The results are recorded in Table 4.
[0123] Table 4
[0124] Example 4. Expression of mature polypeptide mutants D3 and D10 in Bacillus subtilis
[0125] PCR amplification was performed based on the gene sequence of the mature polypeptide mutants D3 or D10. The PCR reaction system was 50 μL, and the specific procedures were the same as in Example 2. The PCR reaction procedure was as follows: 95°C for 3 minutes; 95°C for 15 seconds, 58°C for 15 seconds, and 72°C for 2.5 minutes, 30 cycles; 72°C for 5 minutes; and storage at 4°C. The PCR fragment and plasmid pEB03 were double-digested with restriction endonucleases EcoRI and HindIII, ligated with T4 ligase, and transformed into Escherichia coli DH5α. Recombinant plasmids were obtained after screening and identification.
[0126] Transformation of the recombinant plasmid into Bacillus subtilis 168 was performed as follows: a loopful of glycerol culture of Bacillus subtilis was streaked onto an LB plate (LB medium: 1.0% peptone, 0.5% yeast extract, 1.0% NaCl, and 1.5% agar powder) and incubated overnight at 37°C in a 37°C incubator. A single colony was transferred to 1 mL of LB medium and incubated overnight at 37°C at 200 rpm. Then, 200 μL of the culture was transferred to 200 mL of growth medium (LB medium supplemented with 0.5 M sorbitol) and incubated at 37°C at 200 rpm until the OD reached 0. 600Reach 0.85-0.95, ice bath for 10 minutes, centrifuge at 5000 rpm for 5 minutes at 4°C, then wash 4 times with pre-cooled electroporation medium (electroporation medium: LB medium with 0.5M sorbitol, 10% glycerol), and finally resuspend with 2 mL of pre-cooled electroporation medium. The treated bacterial solution was divided into 80 μL per tube, 1 μL of plasmid was added, transferred to a pre-cooled electroporation cup, placed on ice for 1-1.5 minutes, and then electroporated using an electroporator. The electroporation parameters were set as follows: voltage 2000V, resistance 200Ω, followed by an ice bath for 2 minutes, and then 1 mL of recovery medium (recovery medium: LB medium with 0.5M sorbitol, 0.38M mannitol) was added and cultured at 37°C, 200 rpm for 90 minutes. The bacterial solution was applied to a chloramphenicol (5 μg / mL) LB plate, and the transformant was picked to obtain the target Bacillus subtilis genetically engineered strain.
[0127] A single positive transformant colony was picked from an LB plate containing 5 μg / mL chloramphenicol and inoculated into 20 mL of seed culture medium (0.5% yeast extract, 0.5% tryptone, 1% glucose, 1.8% K2HPO4, 5 μg / mL chloramphenicol) and cultured at 37°C, 220 rpm, and shaking for 8 hours. 2.5 mL of the culture was inoculated into 50 mL of fermentation medium (1.0% tryptone, 0.5% yeast extract, 1.0% NaCl) and cultured at 34°C, 250 rpm, and shaking for 60 hours. The supernatant was analyzed by SDS-PAGE electrophoresis. The expression of the target protein was analyzed by SDS-PAGE to obtain the mature polypeptide mutants BS-D3 and BS-D10, whose amino acid sequences are shown in SEQ ID NO: 3 and SEQ ID NO: 10, respectively.
[0128] BS-D3 and BS-D10 were used for enzyme catalysis, and their ability to catalyze the synthesis of LNT and LNnT was determined.
[0129] Specifically, 128 mM lactose, 20 mM lactose-N-triose II (LNTII), 0.3 mg / mL of the mature polypeptide mutants BS-D3 or BS-D10, 10 mmol / L MgCl2, and 100 mM phosphate buffer (pH 8) were added to a volume of 5 mL, mixed, and reacted at 40°C for 24 hours. The reaction was terminated and the product was purified using a gel column method. The results are recorded in Table 5.
[0130] Table 5
[0131] Example 5. Expression of mature polypeptide mutants D3 and D10 in Aspergillus oryzae
[0132] In this experiment, genomic DNA was extracted from Aspergillus oryzae. The Aspergillus oryzae genomic DNA was used as a template to amplify the Aspergillus oryzae amylase promoter and glycosidase terminator. The promoter, terminator and expression vector backbone pCAMBIA1304 were digested and ligated, respectively. The promoter PamyB and terminator TagdA were linked to the corresponding restriction endonuclease sites to construct the Aspergillus oryzae reading frame and obtain plasmid pCAMBIA001. The genes of mature polypeptide mutants D3 and D10 and plasmid pCAMBIA001 were double-digested with SalI and SpeI, respectively. The two sequences digested with the same restriction endonucleases were ligated. The ligated products were transformed into Escherichia coli competent cells DH5α, and positive clones were screened and expanded for culture. The plasmids pCAMBIA002 and pCAMBIA003 were extracted and the recombinant plasmids were sequenced and verified. The sequencing results showed that the target genes were correct.
[0133] Preparation of competent Agrobacterium tumefaciens EHA105: 1) Inoculate Agrobacterium tumefaciens EHA105 activated on a solid YEB plate into 20 mL of liquid YEB medium supplemented with rifampicin. Incubate at 28°C with shaking at 180 rpm for 24 h. 2) Inoculate 50 mL of liquid YEB medium supplemented with rifampicin at a 1% inoculum of Agrobacterium tumefaciens and shake at 28°C with shaking at 180 rpm until the OD reaches 0. 600 3) Place 50 mL of bacterial suspension on ice for 30 minutes, centrifuge at 5000 rpm for 10 minutes at 4°C, and discard the supernatant. 4) Add 10 mL of pre-chilled 0.1 M CaCl2 solution, resuspend the cells, and place on ice for 30 minutes; centrifuge at 5000 rpm for 10 minutes at 4°C, and discard the supernatant. 5) Add 2 mL of pre-chilled 0.1 M CaCl2 and 2 mL of glycerol, resuspend the EHA105 cells, and aliquot into 135 μL portions for use. Store in a freezer at -70°C until needed.
[0134] Transform competent EHA105 cells with pCAMBIA002 and pCAMBIA003 plasmids using the freeze-thaw method: 1) Thaw competent Agrobacterium tumefaciens EHA105 cells on ice, add 10 μL of the recombinant plasmids pCAMBIA002 and pCAMBIA003, mix thoroughly, and incubate on ice for 30 minutes. 2) Quickly chill the cells in liquid nitrogen for 5 minutes, then immediately incubate in a 28°C water bath for 5 minutes. 3) Incubate on ice for 5 minutes. 4) Add 400 μL of rifampicin-free YEB liquid medium to this mixture, and incubate at 28°C with shaking at 180 rpm for 2 hours. 5) Spread 200 mL of the bacterial culture onto solid YEB plates containing rifampicin and kanamycin, incubate inverted at 28°C for 48 hours, and observe for colony formation. 6) Pick a single colony and transfer it to 20 mL of YEB liquid medium containing rifampicin and kanamycin. Incubate at 28°C with shaking at 180 rpm for 48 hours. Identify and screen positive clones using colony PCR. Extract plasmid DNA from positive clones and perform plasmid PCR analysis.
[0135] Agrobacterium tumefaciens-mediated transformation of Aspergillus oryzae with expression vectors: 1) Inoculate Agrobacterium tumefaciens EHA105 cultures containing different expression vectors into liquid LB medium supplemented with rifampicin and kanamycin and incubate at 28°C at 180 rpm for 24 hours. 2) Add 2 mL of the culture to a mixed medium consisting of 10 mL of liquid LB medium and 10 mL of basal medium and shake incubate at 28°C at 180 rpm for 48 hours. 3) Add 2 mL of the culture to 20 mL of induction medium and shake incubate at 28°C at 180 rpm until the OD600 reaches 0.8. Co-cultivate with Aspergillus oryzae ATCC 10124. 4) Prepare a conidial suspension of Aspergillus oryzae. 5) Mix 135 μL of spore suspension and 135 μL of EHA105 bacterial suspension, then spread the mixture onto a solid induction medium supplemented with acetosyringone and lined with a microporous filter. Incubate the culture at 28°C for 3 days. 6) Remove the microporous filter and invert the plate onto Czapek medium containing hygromycin B and cephalosporin for antibiotic selection at 30°C for 3 days. 7) Remove the microporous filter and continue culturing until resistant colonies emerge. Transfer the selected resistant colonies to a separate selective medium and continue screening. Verify the resistant transformants by genomic PCR.
[0136] Expression of mature polypeptide mutants D3 and D10 (amino acid sequences shown in SEQ ID NO: 3 and SEQ ID NO: 10, respectively): After activation, the engineered Aspergillus oryzae strain was cultured at 30°C for 3 days, the spores were washed with sterile water, and a bacterial suspension was prepared for inoculation. Solid fermentation medium was inoculated with 2% of each strain. Furthermore, the expression medium was incubated at 30°C, 200 rpm, for 6 days. The supernatant was collected and concentrated using a 10 kDa ultrafiltration membrane to obtain the mature polypeptide mutants AO-D3 and AO-D10, respectively.
[0137] AO-D3 and AO-D10 were used for enzyme catalysis, and their ability to catalyze the synthesis of LNT and LNnT was determined.
[0138] Specifically, 128 mM lactose, 20 mM lactose-N-triose II (LNTII), 0.3 mg / mL of the mature polypeptide mutants AO-D3 or AO-D10, 10 mmol / L MgCl2, and 100 mM phosphate buffer (pH 8) were added to a volume of 5 mL, mixed, and reacted at 40°C for 24 hours. The reaction was terminated and the product was purified using a gel column method. The results are recorded in Table 6.
[0139] Table 6
[0140] The above description is merely an embodiment of the present application. All equivalent changes and modifications made within the scope of the present application, as well as research and selection of process parameters such as the temperature of the catalytic reaction, the amount of enzyme added, the reaction time, and the pH value, shall fall within the scope of the present application.
[0141] The above description is merely a preferred embodiment of the present application and is not intended to limit the present application. Although the present application has been described in detail with reference to the aforementioned embodiments, those skilled in the art may still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein with equivalents. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present application shall be included within the scope of protection of the present application.
Claims
1. A mature polypeptide having the activity of synthesizing lactose-N-tetraose (LNT) and lactose-N-neotetraose (LNnT), wherein the amino acid sequence is shown in SEQ ID NO:
1.
2. A mutant of the mature polypeptide according to claim 1, It is characterized in that Obtained by modifying the amino residue at one or more positions selected from positions 182-189, 408-413, 449-454, 481-492, 561-569, 571-573, 593, 591-597, and 599-606 in the mature polypeptide as shown in SEQ ID NO: 1, the mutant having improved catalytic synthesis of LNT and LNnT activity; Preferably, the modification is that the amino acid residues at positions 182-185 are replaced by QPSS to GMNC, the amino acid residue at position 189 is replaced by S to T, and the amino acid residues at positions 408-412 are replaced by QSKKP to YGHYQ, and the amino acid sequence of the mutant is shown in SEQ ID NO: 2; Preferably, the modification is that the amino acid residues at positions 408-413 are replaced by QSKKPY to PMNRLT, and the mutant; Preferably, the modification is that the amino acid residues at positions 481-482 are replaced by ED to DN, and the amino acid residues at positions 484-492 are replaced by TRGDKVNVT to IKANWNESN, and the amino acid sequence of the mutant is shown in SEQ ID NO: 3; Preferably, the modification is that the amino acid residues at positions 450-454 are replaced by YDTTN to KNKET, the amino acid residues at positions 567-569 are replaced by DYV to SLG, and the amino acid residues at positions 571-573 are replaced by WGR to FAK, and the amino acid sequence of the mutant is shown in SEQ ID NO: 4; Preferably, the modification is that the amino acid residues at positions 182-184 are replaced by QPS to RAD, the amino acid residue at position 189 is replaced by S to T, the amino acid residues at positions 408-413 are replaced by QSKKPY to PMNRLT, the amino acid residue at position 593 is replaced by I to V, the amino acid residue at position 600 is replaced by I to L, and the amino acid residue at position 606 is replaced by Y to W, and the amino acid sequence of the mutant is shown in SEQ ID NO: 5; Preferably, the modification is that the amino acid residues at positions 182-184 are replaced by QPS to RAD, the amino acid residue at position 189 is replaced by S to T, the amino acid residues at positions 408-413 are replaced by QSKKPY to PMNRLT, the amino acid residues at positions 449-453 are replaced by IYDTT to SGHGA, the amino acid residue at position 593 is replaced by I to V, the amino acid residue at position 600 is replaced by I to L, and the amino acid residue at position 606 is replaced by Y to W, and the amino acid sequence of the mutant is shown in SEQ ID NO: 6; Preferably, the modification is that the amino acid residues at positions 182-185 are replaced by QPSS to GMNC, the amino acid residue at position 189 is replaced by S to T, the amino acid residues at positions 408-412 are replaced by QSKKP to YGHYQ, the amino acid residues at positions 481-482 are replaced by ED to DN, the amino acid residues at positions 484-492 are replaced by TRGDKVNVT to IKANWNESN, the amino acid residues at positions 567-568 are replaced by DY to SA, the amino acid residue at position 573 is replaced by R to A, the amino acid residue at position 593 is replaced by I to V, the amino acid residues at positions 595-597 are replaced by TGF to DWV, and the amino acid residues at positions 599-606 are replaced by YIGEPTPY to QSLIKYDE, and the amino acid sequence of the mutant is shown in SEQ ID NO: 7; Preferably, the amino acid residues at positions 182-185 are replaced by QPSS to GMNC, the amino acid residue at position 189 is replaced by S to T, the amino acid residues at positions 408-413 are replaced by QSKKPY to PMNRLT, the amino acid residues at positions 450-454 are replaced by YDTTN to KNKET, the amino acid residues at positions 567-569 are replaced by DYV to SLG, the amino acid residues at positions 571-573 are replaced by WGR is replaced by FAK, and the amino acid sequence of the mutant is shown in SEQ ID NO:8; Preferably, the modification is that the amino acid residues at positions 450-454 are replaced by YDTTN to KNKET, the amino acid residue at position 481 is replaced by E to A, the amino acid residue at position 484 is replaced by T to F, the amino acid residues at positions 486-492 are replaced by GDKVNVT to FGNGSGG, the amino acid residues at positions 567-569 are replaced by DYV to SLG, the amino acid residues at positions 571-573 are replaced by WGR to FAK, the amino acid residue at position 593 is replaced by I to V, the amino acid residues at positions 595-597 are replaced by TGF to DWV, and the amino acid residues at positions 599-606 are replaced by YIGEPTPY to QSLIKYDE, and the amino acid sequence of the mutant is shown in SEQ ID NO: 9; Preferably, the modification is that the amino acid residues at positions 182-184 are replaced by QPS to RAD, the amino acid residue at position 189 is replaced by S to T, the amino acid residues at positions 449-453 are replaced by IYDTT to SGHGA, the amino acid residue at position 481 is replaced by E to A, the amino acid residue at position 484 is replaced by T to F, the amino acid residues at positions 486-492 are replaced by GDKVNVT to FGNGSGG, the amino acid residues at positions 567-568 are replaced by DY to SA, the amino acid residue at position 573 is replaced by R to A, the amino acid residue at position 593 is replaced by I to V, the amino acid residues at positions 595-597 are replaced by TGF to DWV, and the amino acid residues at positions 599-606 are replaced by YIGEPTPY to QSLIKYDE, and the amino acid sequence of the mutant is shown in SEQ ID NO: 10; Preferably, the modification is that the amino acid residues at positions 182-185 are replaced by QPSS to GMNC, the amino acid residue at position 189 is replaced by S to T, the amino acid residues at positions 408-413 are replaced by QSKKPY to PMNRLT, the amino acid residues at positions 449-453 are replaced by IYDTT to SGHGA, the amino acid residue at position 481 is replaced by E to A, the amino acid residue at position 484 is replaced by T to F, the amino acid residues at positions 486-492 are replaced by GDKVNVT to FGNGSGG, the amino acid residues at positions 567-568 are replaced by DY to SA, the amino acid residue at position 573 is replaced by R to A, the amino acid residue at position 593 is replaced by I to V, the amino acid residues at positions 595-597 are replaced by TGF to DWV, and the amino acid residues at positions 599-606 are replaced by YIGEPTPY to QSLIKYDE, and the amino acid sequence of the mutant is as shown in SEQ ID Shown in NO:
11.
3. A polynucleotide encoding the mature polypeptide or a mutant thereof according to claim 1.
4. A nucleic acid construct comprising the polynucleotide of claim 3 and one or more regulatory sequences operably linked thereto.
5. An expression vector comprising the polynucleotide according to claim 3, or comprising the nucleic acid construct according to claim 4.
6. A transformed host cell comprising the transformed nucleic acid construct according to claim 4 or the expression vector according to claim 5.
7. An enzyme agent or enzyme composition comprising the mature polypeptide or a mutant thereof according to claim 1.
8. The method for expressing the mature polypeptide and / or its mutant according to claim 1, include: (a) culturing a host cell under conditions suitable for expressing the mature polypeptide and / or its mutant; and (b) recovering the mature polypeptide and / or its mutant; Preferably, the step (a) comprises: culturing a host cell comprising a nucleic acid construct comprising a nucleotide sequence encoding the mature polypeptide and / or its mutant under conditions conducive to the production of the mature polypeptide and / or its mutant; Preferably, the step (a) further comprises: first constructing a recombinant plasmid encoding the above-mentioned mature polypeptide and / or its mutant gene, and then introducing it into a host cell; Preferably, the host cell in step (a) comprises a recombinant engineered strain of a host cell; Preferably, the step (b) further comprises isolating and purifying the mature polypeptide and / or its mutant; Preferably, the step (b) comprises: after the expression is completed, disrupting the cultured cells to obtain a crude enzyme solution containing the mature polypeptide and / or its mutant; optionally, further comprising the step of separating and purifying the mature polypeptide and / or its mutant. Preferably, the host cell is selected from the group consisting of Bacillus and Escherichia; further preferably, selected from the group consisting of Escherichia coli, Escherichia hermanii, Escherichia fergusonii, Bacillus mycoides, Bacillus cereus, Bacillus licheniformis, Bacillus brevis, Bacillus circulans and Bacillus subtilis; Further preferably, the host cell is Bacillus circulans, Bacillus subtilis or Bacillus licheniformis; Preferably, the mold is selected from: Aspergillus and Trichoderma; more preferably, it is a cell of Trichoderma viride, Trichoderma reesei, Aspergillus oryzae, Aspergillus fumigatu, Aspergillus niger, or Aspergillus flavus; more preferably, the host cell is an Aspergillus oryzae cell; Preferably, the yeast cell is selected from the group consisting of: Candida, Hansenula, Kluyveromyces, Pichia, Saccharomyces, Schizosaccharomyces, and Yarrowia cells; further preferably, it is a Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces marxinus, Yarrowia lipolytica, Rhodotorula graminis, Saccharomyces pastorianus cell; further preferably, it is a Saccharomyces cerevisiae, Kluyveromyces lactis, or Kluyveromyces marxinus cell; In the method for expressing the mature polypeptide and / or the mature polypeptide mutant, the host cell includes a wild strain isolated from nature, a mutant strain after physical and chemical mutagenesis, or an engineered bacterium after genetic engineering.
9. Use of the mature polypeptide or its mutant according to claim 1 in the synthesis of LNT and LNnT; Preferably, in the application, a carbohydrate selected from lactose and / or its derivatives is used as a reaction substrate; Preferably, in the application, lactose and lactose-N-triose (Lacto-N-triose, LNTII) are used as reaction substrates; Preferably, in the application, an aqueous solvent or a solution containing solid matter is used as the reaction solvent.
10. A method for synthesizing LNT and LNnT, comprising using the mature polypeptide shown in SEQ ID NO: 1 or a mutant thereof as a catalyst; Preferably, the method uses a carbohydrate selected from lactose and / or its derivatives as a reaction substrate; Preferably, the method uses lactose and lactose-N-triose as reaction substrates; Preferably, the method uses an aqueous solvent or a solution containing solids as the reaction solvent.
Citation Information
Patent Citations
Improved enzyme variants of lactase from kluyveromyces lactis
CN105899659A
Heat-resistant beta-galactosidase mutant with transglycosylation and preparation method of mutant
CN105950589A
Modified beta-galactosidase
CN106604991A
Application of Haloferula sp. beta-N-acetylhexosaminidase to synthesis of breast milk oligosaccharide
CN111534503A
Enzyme derived from paenibacillus pabuli and capable of producing galactooligosaccharide and method for producing galactooligosaccharide
CN112351990A
